文献速递临床试验与 GCP

绿茶摄入对住院COVID-19患者实验室指标与症状影响的随机对照试验结构化方案

Green tea intake and its effect on laboratory parameters and disease symptoms in hospitalised patients with Covid 19: a structured protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-08-03

本随机对照试验方案旨在评估绿茶摄入对轻中度COVID-19住院患者疾病症状及实验室参数(CRP、ESR、全血细胞计数)的影响。干预组每日两次服用含450 mg绿茶提取物的胶囊,对照组服用安慰剂,疗程14天,采用双盲、平行分组(1:1)设计,计划每组37例。

要点

  • 双盲随机对照试验评估绿茶提取物辅助治疗COVID-19。
  • 主要结局为14天后症状及CRP、ESR、CBC变化。
  • 干预组每日两次服用450 mg绿茶提取物胶囊,共14天。

核心结论

  • 该方案拟通过随机双盲对照试验评估绿茶摄入对轻中度COVID-19住院患者症状和实验室指标的影响,目前尚未报告结果。

研究设计与样本

  • 随机、双盲、平行分组(1:1)探索性临床试验,在伊朗Yasuj Shahid Jalil医院招募≥18岁经RT-PCR确诊的COVID-19住院患者。

关键数值与推荐

  • 干预组:每日两次、午餐和晚餐后服用两粒含450 mg绿茶提取物的胶囊,联合常规治疗,持续14天;对照组服用外观相似的安慰剂胶囊联合常规治疗。
  • 主要结局为14天后疾病症状及CRP、ESR、CBC相较于对照组的变化。
  • 样本量基于CRP最小临床重要差异(MCID)确定,高CRP水平定义为>2.6 mg/L。
  • 排除标准包括妊娠或哺乳、弥散性血管内凝血或其他凝血病、严重充血性肾衰竭、过去30天内参与过临床试验。

临床怎么用

  • 该方案为绿茶提取物作为COVID-19辅助治疗的临床研究提供设计框架,结果尚未产出,暂不能指导临床实践。

局限性

  • 该文件仅为试验方案,尚无结果数据;试验注册为回顾性注册(2021年6月4日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The current randomized controlled trial (RCT) will be conducted to assess the effect of green tea intake on disease symptoms and laboratory parameters including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and complete blood count (CBC) in patients with mild-to-moderate Covid-19 infection. TRIAL DESIGN: Randomized, double-blinded, parallel (1:1 ratio) clinical trial exploratory study PARTICIPANTS: We will recruit patients with COVID-19 infection admitted to Yasuj Shahid Jalil Hospital in Yasuj City, Kohgiluyeh and Boyer-Ahmad Province, Iran. Participants' inclusion criteria are as follows: Inclusion Criteria Patients aged ≥18 years COVID-19 diagnosis according to real-time polymerase chain reaction (RT-PCR) Exclusion Criteria Pregnancy or lactation Disseminated intravascular coagulation or any other types of coagulopathy Severe congestive kidney failure Having a history of participating in a clinical trial during the last 30 days INTERVENTION AND COMPARATOR: Intervention: Two capsules containing 450 mg green tea extract along with routine treatment for COVID-19 patients in the intervention group. Two capsules containing placebo plus routine treatment for patients with COVID-19 infection. Capsules will be taken twice a day, after lunch and dinner, for 14 days. MAIN OUTCOMES: Changes in disease symptoms and laboratory parameters including CRP, ESR, and CBC after 14 days of the intervention compared to control group. RANDOMISATION: Eligible patients will be randomly assigned into the intervention or control group in a 1:1 ratio. Randomization will be performed based on 8 permuted blocks with block sizes of 10, and patients in the intervention and control groups will be matched according to sex and age categories. Randomization will be done using computer-generated random numbers ( Randomization.com ) BLINDING (MASKING): The appearance of placebo and green tea capsules will be similar in terms of shape and color, and they will be packed in the same bags that will be prepared by the company. Also, the researcher and all participants will not be aware of the divisions until the end of the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The total sample was determined based on CRP MCID in which high CRP levels were considered >2.6 mg/L. Accordingly, a total sample size of 37 patients for each intervention group was required. TRIAL STATUS: The protocol is Version 1.0, on June 5, 2021. Recruitment will start on July 11, 2021, which is anticipated to be completed by September 21, 2021. TRIAL REGISTRATION: IRCT20150711023153N3 ( https://www.irct.ir/trial/55948 ) retrospectively registered on June 4, 2021 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting was eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mahmoodi S, Yousefi M, Sadeghi O, et al. Green tea intake and its effect on laboratory parameters and disease symptoms in hospitalised patients with Covid 19: a structured protocol for a randomized controlled trial. Trials. 2021. PMID: 34344427. doi:10.1186/s13063-021-05462-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。